Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Josephine Diaz

Physician Assistant, Medical Suffield, CT Physician Assistant

NPI 1871517342 CMS profile 10923982

162 Mountain Rd, Suffield, CT 06078

Open in the dashboard

General payments

$20,207

1,101 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Josephine Diaz of Suffield, CT is reported in the CMS Open Payments database as having received $20,207 across 1,101 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,772 246
2024 General $3,941 219
2023 General $4,080 220
2022 General $3,706 207
2021 General $3,709 209

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Josephine Diaz
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Josephine Diaz were reported at $4,772. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Josephine Diaz Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $3,709 $156 $41–$563 $132
2022 $3,706 $185 $55–$649 $149
2023 $4,080 $199 $58–$717 $160
2024 $3,941 $206 $62–$740 $164
2025 $4,772 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $4,678 286 payments
  2. AstraZeneca Pharmaceuticals LP $1,847 93 payments
  3. GlaxoSmithKline, LLC. $1,516 86 payments
  4. Novo Nordisk Inc $1,310 70 payments
  5. Lilly USA, LLC $924 55 payments
  6. Pfizer Inc. $900 57 payments
  7. Amgen Inc. $686 50 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $663 32 payments
  9. Abbott Laboratories $561 32 payments
  10. E.R. Squibb & Sons, L.L.C. $467 23 payments
  11. Other $6,654 317 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $20,101 1,097 payments
  2. Education $92 3 payments
  3. Long term medical supply or device loan $15 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $1,698 103 payments
  2. QULIPTA $1,461 91 payments
  3. TRELEGY ELLIPTA $1,328 76 payments
  4. UBRELVY $1,204 78 payments
  5. RYBELSUS $916 45 payments
  6. Ozempic $903 45 payments
  7. BREZTRI $851 44 payments
  8. VRAYLAR Neuroscience $624 40 payments
  9. AIRSUPRA $605 27 payments
  10. EVENITY $463 20 payments
  11. Other $14,300 782 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 152 drugs

Part D claims

8,114

Median for Physician Assistant: 241

Drug cost

$1,625,984

Median for Physician Assistant: $4,110

Branded share of claims

29%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 337 $413,568
Mounjaro Tirzepatide Brand 138 $180,196
Farxiga Dapagliflozin Propanediol Brand 110 $106,797
Ingrezza Valbenazine Tosylate Brand 12 $104,976
Jardiance Empagliflozin Brand 87 $103,953
Eliquis Apixaban Brand 94 $69,466
Repatha Sureclick Evolocumab Brand 70 $57,698
Myrbetriq Mirabegron Brand 61 $46,509
Prolia Denosumab Brand 22 $38,050
Vraylar Cariprazine Hcl Brand 19 $37,906

The 10 drugs with the highest cost, of 152 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 49 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$414 19 —
TRELEGY ELLIPTA
$310 42 —
AIRSUPRA
$221 — —
UBRELVY
$217 — —
ELIQUIS
$193 94 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 49 with Patron

Records

1,101 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record